Picture loading failed.

Pre-Made Lumretuzumab biosimilar, Whole mAb, Anti-ERBB3/Erbb-3 Antibody: Anti-ErbB-3/FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB-3/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lumretuzumab (INN; development code RG7116) is a humanized monoclonal antibody designed for the treatment of cancer.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-328-1mg 1mg 3090
GMP-Bios-ab-328-10mg 10mg 21890
GMP-Bios-ab-328-100mg 100mg 148000
GMP-Bios-ab-328-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Lumretuzumab biosimilar, Whole mAb, Anti-ERBB3/Erbb-3 Antibody: Anti-ErbB-3/FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB-3/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody
INN Name Lumretuzumab
TargetErbb-3
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusDiscontinued
100% SI Structure4leo:AB
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2014
Year Recommended2015
CompaniesRoche
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedBreast cancer;Solid tumours
Development TechGlycoMAb Technology